The Annexure

News to 9 October 2026 ·

Desk›Healthcare› Auro Laboratories Ltd

Auro Laboratories Ltd

BSE 530233 · NSE AUROLAB · ISIN INE292C01011 · Group X · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹232.00

-3.15%

BSE close, 28 August 2026

Market cap

₹144.59 cr

0.6 cr shares · Micro cap

Free float

₹65.50 cr

as published

P/E · P/B

30.9× · 3.33×

EPS ₹7.52 · BV ₹69.67

FY25-26 rev / PAT

30.74 / 3.53

₹ cr, as filed

Filings, window

8

2 selected · 25%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

52-WK LOW ₹159.00 52-WK HIGH ₹317.00 ₹232.00 46% of range
Against 52-week high-26.8%
Against 52-week low+45.9%
Day change-3.15%
Size bandMicro cap
Index membershipNone

Valuation as published by BSE

Earnings per share₹7.52
Price / earnings30.85×
Price / book3.33×
Book value — derived, price ÷ P/B₹69.67
Return on equity10.80%
Operating margin38.94%
Net margin11.93%

Consistency check

P/B ÷ P/E, which must equal ROE
10.79%
ROE as published
10.80%

Results ₹ crore, as filed

RevenueNet profit one scale across all three periods, ₹ crore

PeriodRevenue ₹cr Net profit ₹cr EPS ₹OPM NPM
Jun-26 · Q 8.77 1.05 1.68 38.94% 11.93%
Mar-26 · Q 9.83 0.97 1.56 39.11% 9.87%
FY25-26 30.74 3.53 5.67 38.62% 11.49%

Quarter on quarter

Revenue, quarter on quarter
-10.8%
Net profit, quarter on quarter
+8.2%
Operating margin, quarter on quarter
-17 bps

Disclosure profile 8 filings in the window

0 median 17.0 p75 · 25 sector max 52 8 8th percentile of 300 Healthcare filers
Shaded is the middle half of the sector, 12 to 25 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.
TagFilings
Selected
Board Outcome1
Results1
Selected sub-total2
Procedural
AGM / EGM2
Newspaper Publication2
Board Meeting1
Trading Window1
Procedural sub-total6
Total8

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group X, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 93 trading days

8 filings · 2 selected · busiest 2026-08-14

Filing rhythm · the twelve most recent

2026-07-202026-09-23

SelectedProcedural

Filings

8 in the window · 8 earlier on record

  1. 23 September 2026 ·

    Trading Window

    Closure of Trading Window

    Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 we wish to inform you that, the trading window for dealing in the securities of the company will remain closed w.e.f. ....

    Insider Trading / SAST / Closure of Trading Window View filing →

  2. 17 August 2026 ·

    Newspaper Publication

    Newspaper Publication

    Auro Laboratories Limited has submitted the clippings of newspaper publications of the Un-audited Financial Results for the quarter ended June 30, 2026.

    Company Update / Newspaper Publication View filing →

  3. 14 August 2026 ·

    Results

    Un-Audited Financial Results For The Quarter Ended June 30, 2026.

    Auro Laboratories Limited has submitted the Unaudited Financial Results for the Quarter ended June 30, 2026.

    Result / Financial Results View filing →

  4. 14 August 2026 ·

    Board Outcome

    Board Meeting Outcome for Outcome Of Board Meeting Held On August 14, 2026.

    Auro Laboratories Limited has submitted the Outcome of the Board Meeting held on August 14, 2026

    Board Meeting / Outcome of Board Meeting View filing →

  5. 13 August 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Auro Laboratories Limited has submitted the Scrutinizer Report of 37th AGM held on August 11, 2026.

    AGM/EGM / AGM View filing →

  6. 11 August 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Auro Laboratories Limited has submitted the Proceedings/Outcome of the 37th Annual General Meeting held on August 11, 2026.

    AGM/EGM / AGM View filing →

  7. 10 August 2026 ·

    Board Meeting

    Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended June 30, 2026.

    Auro Laboratories Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Unaudited Financial Results ....

    Board Meeting / Board Meeting View filing →

  8. 20 July 2026 ·

    Newspaper Publication

    Newspaper Publication

    With reference to Regulation 47 of SEBI (LODR) Regulations 2015, attached herewith newspaper cuttings of Public Notice of the 37th AGM, information on evoting and other related information.

    Company Update / Newspaper Publication View filing →

RSS feed for Auro Laboratories Ltd · the 50 most recent filings